ARCH Venture Fund XII, L.P.

Overview

• HeadquartersDE¹
• Legal formLimited Partnership
• Kind of organizationVenture capital fund¹

See how the biggest companies compare on our leaderboards

Corporate structure

ARCH Venture Fund XII, L.P. sits at the top of its group. 7 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G; stakes of 5% or more it reported on Schedules 13D and 13G (6 companies). Each entity in the chart links to its source.

Leadership

Named in SEC Form D filings

People the company listed in its private-offering notices.

• General Counsel of the GP LLCJason L. Doren named Apr 1, 2022²
• Managing Director of the GP LLCKeith L. Crandell named Apr 1, 2022²
• Managing Director of the GP LLCKristina Burow named Apr 1, 2022²
• Managing Director of the GP LLCMark L. McDonnell named Apr 1, 2022²
• Managing Director of the GP LLCPaul T. Berns named Apr 1, 2022²
• Managing Director of the GP LLCRobert T. Nelsen named Apr 1, 2022²
• Managing Director of the GP LLCSteven L. Gillis named Apr 1, 2022²

Filings

2 filings to the SEC since October 2021: 2 private raises. The latest 2:

1. Apr 1, 2022D/A EDGAR
2. Feb 3, 2022D EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Stakes it holds

ARCH Venture Fund XII, L.P. has told the SEC it owns more than 5% of 6 companies, latest first (Schedules 13D and 13G).

• Parabilis Medicines, Inc.SCHEDULE 13G Aug 14, 2026³
• Seaport Therapeutics, Inc.SCHEDULE 13D May 6, 2026⁴
• Neumora Therapeutics, Inc.SCHEDULE 13D/A Oct 2, 2023 to Apr 1, 2026⁵
• Metsera, Inc.SCHEDULE 13D/A Feb 10, 2025 to Nov 14, 2025⁶
• Prime Medicine, Inc.SCHEDULE 13D/A Feb 22, 2024 to Aug 11, 2025⁷
• Rapport Therapeutics, Inc.SC 13G Nov 14, 2024⁸

Money raised

Private offerings the company reported to the SEC on Form D.

1. Feb 4, 2022Raised $2.8 billion in a private offering of securities Form D: $2.9 billion offered in all Form D